Zimbabwe has rejected a substantial American health deal valued at 367 million US dollars (272 million pounds) spanning five years because of the United States' demand for sensitive information.
The decision became public after a official document from December was leaked, which showed President Emmerson Mnangagwa felt the deal was "skewed".
An official representative later stated that the US was requesting genetic material for scientific study and commercial gain but was unwilling to share the benefits from any future medical innovations.
"We must now begin the difficult and regrettable task of ending our support in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont publicly.
The US Embassy indicated the US had provided over $1.9bn in health funding to Zimbabwe during the past twenty years.
A physicians' group in Zimbabwe has appealed for more negotiations to reach a agreement suitable to both sides so the nation's vital HIV programme can proceed.
Wider Background
This development follows a similar situation in Kenya, where a high court halted a related deal with the US following concerns were raised about the security of citizens' medical information.
Since returning to the presidency recently, US President Donald Trump has reduced overseas assistance and closed the key foreign aid agency.
USAID had administered assistance for the US government, but Trump argued its expenditure was "inefficient" and his government was pursuing direct bilateral deals to enhance openness and accountability.
As per statements, 16 African countries have so far signed similar agreements, representing more than $18.3bn in committed funds.
Details of the Rejected Agreement
This assistance for Zimbabwe was intended to funded "tackling HIV/Aids, TB, malaria, healthcare for mothers and children, and preparing for epidemics".
"We are confident this cooperation would have delivered significant benefits for Zimbabwean communities, especially the 1.2 million currently on antiretroviral therapy via American-funded programmes," the Ambassador added.
However, government spokesperson Nick Mangwana said the arrangement was "asymmetrical".
"Zimbabwe was being asked to surrender its biological resources and data for a long time, with no corresponding assurance of benefiting from any scientific breakthroughs – like new medicines or tests – that could result from that shared data," Mangwana explained.
"Effectively, our nation would provide the basic resources for scientific discovery with no assurance that the final treatments would be accessible to our people should a future disease outbreak emerge."
National Interest and Global Health
Mangwana further noted that the American exit from the World Health Organization (WHO) and its pursuit of bilateral deals were upending frameworks previously set up through the global health agency.
The spokesperson cited its Pathogen Access and Benefit Sharing scheme designed to deal with future global health emergencies.
"This system is designed to ensure that when a nation provides its samples, the resulting advantages – such as vaccines and treatments – are distributed fairly, not monopolised solely by those with the resources to develop them."
These objections over the US deal "must not be interpreted as anti-American sentiment," he added.
"We encourage ongoing dialogue with our US partners on how subsequent collaboration could be designed in a manner that respects the independence and interests of both nations."
Medical Community Response
Medical experts stated it understood the official position, but suggested that talks need to persist since much of the nation's HIV programmes depended on external financing.
"Where specific concerns arise, such as those relating to data governance or agreement terms, these can often be resolved through technical clarification and mutually agreed protections," the group added.
The halted deal underscores the complex tensions between receiving much-needed international aid and protecting local interests in an increasingly interconnected world.